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Background: Despite validated guidelines, management of mild head injury (MHI) is still associated with excessive
computed tomography (CT) scanning. Reports concerning serum levels of S100B have shown promise concerning
safe reduction in CT scanning but clinical validation and actual impact on patient management is unclear. In 2007,
S100B was introduced into emergency department (ED) clinical management routines in Halmstad, Sweden. MHI
patients with low (<0.10 mikrogram/L) levels of S100B could be discharged without CT. Our aim was to examine
the clinical impact and performance of S100B in clinical use for MHI patients.
Methods: Adult ([≥]18 years) patients with MHI (GCS 14–15, loss of consciousness and/or amnesia and no
additional risk factors) and S100B sampling within 3 hours were prospectively included in this validation study.
Patients were managed according to the adapted guidelines and management was documented. Outcome was
determined with a questionnaire 3 months post-trauma and medical records to identify significant intracranial
complications such as new neuroimaging, neurosurgery and/or death related to the trauma.
Results: 512 patients were included. 24 (4.7%) showed traumatic abnormalities on CT and 1 patient died (0.2%).
138 patients (27%) had normal S100B levels and 374 patients (73%) showed elevated S100B levels. No patients
with a normal S100B level showed significant intracranial complication. 44 patients (32%) were managed with CT
despite the guidelines recommending discharge (all these CT scans were normal) and 28 patients (7%) were
discharged despite a CT recommendation (follow-up was normal in all these patients). S100B had a sensitivity of
100% (95% CI 83-100%) and a specificity of 28% (95% CI 24-33%) for significant intracranial complications.
Conclusion: The clinical use of S100B within our existing guidelines for management of MHI is safe and effective.
Adult MHI patients, without additional risk factors and with normal S100B levels within 3 hours of injury, can safely
be discharged from the hospital.Background
Traumatic brain injuries (TBI) result in almost 17 000
emergency department (ED) visits per year in Sweden
and account for more than 1 million ED visits each year
in both the United States of America and the United
Kingdom [1-3]. Most of them (up to 95%) are classified
as mild head injuries (MHI) [4], commonly defined as a
head trauma with short loss of consciousness (LOC) or
amnesia for the accident, Glasgow Coma Scale (GCS)
14–15 and no neurological deficits at the time of med-
ical inspection. These patients have been notoriously* Correspondence: dr.johan.unden@gmail.com
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distribution, and reproduction in any mediumdifficult to manage since they have a low, but not negli-
gible, risk of an intracranial complication, which may be
life threatening [5]. Pathological computed tomography
(CT) results after MHI are found in 0.5-20% of patients
(0-8% for significant complications) and the need for
neurosurgical intervention is between 0-1% [6].
Scandinavian guidelines for management of minimal,
mild and moderate head injuries were presented by the
Scandinavian Neurotrauma Committee (SNC) in the
year 2000 [1]. For patients with GCS 14–15 and LOC
and/or amnesia, these guidelines recommend head CT
or, as a secondary option, hospital admission with clin-
ical observation. Similar guidelines have been published
from other groups [7-9] and all have the same goal;
to stratify patients with MHI into risk groups for intra-
cranial complications. In order to ensure that guidelinestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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substantial over-triage to CT has historically been
accepted (between 80–99,5% of CT’s after MHI are nor-
mal [6,10]). In recent years, however, focus has been put
on reducing unnecessary CT scans due to limitations in
health care resources along with reports of increased
cancer risks associated with exposure to medical radi-
ation [11,12]. External comparisons of different clinical
decision rules have shown favourable results for the
SNC guidelines [10,13].
During the last fifteen years, protein S100B has received
increasing attention as a possible biomarker for neurological
disease [14,15]. Low serum levels of the protein are found
in healthy individuals while patients with head trauma have
a level of S100B proportionate with the severity of their
brain injury [16]. S100B has a very high sensitivity for brain
injuries, possibly even higher than CT [17], which would re-
sult in a high negative predictive value (NPV) in the MHI
setting. Based on several studies from separate research
groups and a meta-analysis [18-22], S100B has shown a
NPV of over 99% for intracranial complications and close
to 100% for neurosurgical lesions after MHI. Considering
the theoretical CT reduction of 30%, S100B seems useful in
the management of this patient group.
Despite these promising studies, S100B has not been
validated in clinical practice and the impact on decision-
making in a real-life setting is unclear. The aim of this
study was therefore to examine the clinical impact and
diagnostic performance of serum S100B levels in actual
management of MHI patients.
Methods
Study setting and population
In early 2007, S100B was introduced into clinical practice
within the existing SNC guidelines to create new local
management routines (Figure 1). The addition of S100B
was applied to a group of patients, typically considered as
intermediate risk for intracranial complication, where CT
is normally recommended. We set the time interval for
S100B sampling at 3 hours post injury, reflecting the evi-
dence available in 2007 [23]. Also, evidence for S100B use
in children at this time was relatively weak and the new
guidelines were therefore used only in adults.
After a 6 months adjustment period, we undertook
a prospective cohort validation study in Halmstad
Regional hospital, Sweden, from November 2007 to May
2011, to evaluate the adapted guidelines explained above.
Our hospital is a level II trauma centre with 24-hour
emergency care, anaesthesiology, radiology, surgery and
intensive care.
We consecutively enrolled all adult patients with MHI
and S100B sampling. Initial inclusion criteria were there-
fore analogous to the MHI group in the SNC guidelines;
adult patients with acute trauma to the head with GCS14–15 during examination and loss of consciousness < 5
minutes and/or amnesia, with the addition of the S100B
sample. Patients with anti-platelet agents (such as as-
pirin or clopidogrel) were included. Exclusion criteria
were age less than 18 years, non-Swedish citizens (diffi-
cult to follow up), neurological deficits, additional risk
factors from the SNC guidelines (therapeutic anticoagu-
lation or haemophilia, clinical signs of depressed skull
fracture or skull base fracture, posttraumatic seizures,
shunt-treated hydrocephalus and multiple injuries) and
patients where serum sampling for S100B was done
more than 3 hours post-injury.
Our goal was to include 500 patients in the study,
based upon consensus in the study group when consid-
ering the aim of the study. A sample size calculation was
not performed.
The study was conducted in accordance to the Helsinki
Declaration and approved by the Lund regional ethical
committee, Lund, Sweden (reference number 19/2007).
Since the study did not involve any change in patient
management and based upon clinical practice, informed
consent was not necessary and the ethics committee
concurred with this decision.
Blood sampling and biochemical analysis
A 5ml blood sample was drawn from each patient’s
cubital vein in the ED. Samples were analysed with the
fully automated ElecsysW S100 (Roche AB) at the Clinical
Chemistry Department of Halmstad Regional hospital,
Sweden. Roche AB report a range between 0.005 μg/L
and 39 μg/L and a within-series coefficient of variance of
<2.1%. Based on the available evidence at this time, we
chose a cut-off level for normal levels of less than
0.10μg/L and a window of sampling of 3 hours from the
time of the accident [19,23]. Lab results were available to
treating physicians within 1 hour after sampling.
CT examinations
CT scans were performed with a GE VCT Ligthspeed 64
multislice detector with a 0,625/0,625mm, 0,5 seconds ro-
tation time and pitch of 0,531:1. 10mm thick slices were
used as part of the standard CT protocol for these
patients. CT scans are always analysed by a board certified
radiologist and confirmed by a consultant radiologist.
Since S100B was used clinically, radiologists were not
blinded to S100B results. A CT scan was considered posi-
tive if any signs of cranial (skull fracture) or intracranial
pathology (hematoma, air or contusion) were present.
Standardized assessment of patients
Supervised interns and surgical residents from the ED of
the Halmstad Regional Hospital assessed patients. These
physicians underwent several educational sessions on
evaluating patients with MHI using the new guidelines.
Traumatic head injury (> 18 years) without risk factors
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Figure 1 Modified Scandinavian Neurotrauma Committee (SNC) guidelines including S100B sampling. Dotted line indicates secondary
management option. GCS = Glasgow Come Scale, CT = Computed Tomography.
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for all non-severe head injury patients even though
deferral from these due to clinical judgement was allowed.
Data registration and follow-up
Details of how patients were managed, including patient
characteristics, type of injury, patient history, medications,
clinical examination results, CT results, admission type
and duration were documented in an Excel spreadsheet.
Patients were asked to answer a questionnaire sent by
mail 3 months after the injury, which was repeated if no
answer was received. For patients who did not return the
questionnaire after these attempts, a blinded assessor con-
ducted the questionnaire via telephone. Included in this
questionnaire were questions that would identify a signifi-
cant intracranial complication [7]. In cases where patients
could not be reached by mail or telephone, medical
records and national mortality databases were consulted
for evidence of complications and/or death. Considering
the rigid and transparent organisation of the health care
system in Sweden, these methods would identify all
patients with significant (enough to result in new neuroi-
maging, neurosurgery or death) intracranial complications.Our outcome endpoint for the study was significant
intracranial complication, which was defined as either a
traumatic complication on emergency CT or, via follow-
up, new neuroimaging showing traumatic intracranial
complication or neurosurgery and/or death due to an
intracranial complication.
Sensitivity, specificity, positive and negative predictive
values were estimated from cross tabulation between
S100B and significant intracranial complications and
reported with corresponding 95% confidence intervals.
Values are reported to two significant figures.
Results
Between November 2007 and May 2011, we enrolled
512 patients (see Figure 2 for inclusion process and
Table 1 for descriptive statistics). 26 patients had cranial
CT pathology but only 24 (4.7%) showed traumatic
abnormalities (isolated skull fracture n=3, cerebral con-
tusions n=7, acute subdural hematoma n=3, intracranial
air n=1, combinations of traumatic intracranial findings
n=10). 2 patients showed CT pathology not related to
trauma (cerebral tumour n=1 and pathological intra-
cranial calcification n=1). No patients needed neurosurgical
Patients with MHI
N= 565
Not Swedish residents n=8
Children  n= 15
S100B sampling more than 3 
hours post injury n= 7







Figure 2 Inclusion process. MHI = Mild Head Injury.
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an 83-year-old man with an S100B level of 0.23μg/L and a
CT showing expansive cerebral contusions who died from
increased intracranial pressure. Neurosurgical care was
denied due to advanced age.
138 patients (27%) had a S100B level less than
0.10μg/L and 374 patients (73%) showed a S100B level
higher or equal to 0.10μg/L. Details of how patients were
managed are presented in Figure 3. The follow up ques-
tionnaire was completed for 414 patients (81%). Medical
records and the mortality database were successfully
checked for all remaining patients. No patients with a
normal S100B level showed significant intracranial com-
plication, either on CT or on follow-up, see Figure 3.
Over-triage (CT or admission performed when the guide-
lines recommended discharge) occurred in 44 patients
(32%) with normal S100B levels. 15 of these had a CT scan,
20 were admitted and 9 patients had both a CT and admis-
sion. All of these patients had normal CT findings and/or
normal follow-up. Under-triage (not performing a CT when
recommended) occurred in 28 patients (7%) with elevated
S100B levels. None of these patients had any significant
intracranial complications on follow-up.
S100B displayed a sensitivity and NPV of 100% for sig-
nificant intracranial complications, a specificity of 28%
and a positive predictive value (PPV) of 6%, see Table 2.Table 1 Descriptive statistics
S100B < 0.10μg/L S100B ≥ 0.10μg/L All
Male 85 (61.6%) 229 (61.3%) 314 (61.5%)
Female 53 (38.4%) 145 (38.7%) 198 (38.5%)
Age (mean) 32.6 46.6 42.2
Total 138 374 512Discussion
The first report concerning serum S100B as a possible
biomarker in MHI was published in 1995 [15]. Since
then, numerous reports and a meta-analysis, document-
ing the potential of S100B to safely reduce CT scans fol-
lowing MHI, have increased the evidence for clinical use
[20-24]. However, actual clinical validation has never
been reported despite the biomarker being used clinic-
ally in several European countries. In 2007, S100B was
introduced as a clinical tool in the management of MHI
in our hospital, in an attempt to reduce CT scans after
these injuries. This study shows that this implementation
has been successful and that S100B, using a cut-off of
less than 0.10 μg/L for normal values and a time window
of 3 hours from injury, shows similar predictive values
to the derivation studies.
Low compliance to guidelines is a common problem
[5]. 32% of patients with normal S100B levels were over-
triaged with CT, admission or both. None of these had
any intracranial complications. It is natural to expect
caution when using new routines, especially concerning
an injury where biomarkers have never been used before.
Also, physicians must always be free to exert clinical
judgement since management guidelines are merely an
aid in the clinical process. Some patients cannot be sent
home from the ED irrespective of S100B and/or CT
findings (for example; elderly patients without support
in their home environment, serious intoxication and
patients with other injuries).
Our adapted guidelines are based upon the evidence-
based SNC management guidelines from the year 2000
[1]. Since this publication, considerable new evidence
has emerged in this field, including validated guide-
lines based upon patient history and clinical examination
[7-9]. The impact of including S100B in other guidelines
MHI without risk factors and S100B < 3 hours
n=512
S100B < 0.10 µg/L
n=138


























Figure 3 Patient management in the study cohort including number of intracranial injuries. CT= computed tomography, MHI= mild head
injury, SICC=Significant Intracranial Complication.
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accurate in comparison studies [8,10] so the implemen-
tation of S100B into these is justifiable. Despite this, the
examination of S100B within other guidelines is natur-
ally warranted.
Owing to the predictive properties of S100B, the bio-
marker is best adapted into an intermediate risk group
of patients, such as in this study. The prevalence of trau-
matic intracranial injury in this group was 4.7%, similar
to other cohorts. These patients would normally receive
a CT recommendation according to the SNC guidelines,
which is justifiable considering the prevalence level.
However, interpreting S100B levels in minimal head in-
jury would lead to substantial over-triage (false positives)
and using levels in more severe head injuries could lead
to under-triage and may risk missing important compli-
cations (false negatives) [12].
This study has several limitations. Firstly, one may
argue that our method of determining the outcome
measure, significant intracranial complications, may missTable 2 Cross tabulation showing statistical values for S100B
SICC + Total = 24
S100B ≥ 0.10μg/L 24
Total = 374




SICC = Significant intracranial complications, NPV= Negative predictive value, PPV=patients that may in fact have CT abnormalities. How-
ever, if these exist, these abnormalities would not have
resulted in any change in management and/or outcome
for these patients. The organisation of the state-owned
Swedish health care system, with personal identification
numbers connected with all medical journals, allows us
to accurately identify new neuroimaging, neurosurgery
and/or death in all patients who were not followed up
with the questionnaire and therefore identifies any cases
of important intracranial injury. This also allows us to
minimise recall bias arising from the questionnaire. Sec-
ondly, none of our patients needed neurosurgery. If this
was the endpoint, one could suggest that all our patients
could have been discharged without S100B or CT. This
management, however, would not be accepted in Sweden
and the results must be considered in relation to the
existing guidelines, which recommend CT in all these
patients, similar to guidelines in other countries. Thirdly,
the timing of S100B sampling after injury may be of im-
portance. We used a time window of 3 hours based uponand significant intracranial complications
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short half-life of S100B in blood [25]. Recently, a large pro-
spective study has utilised a time window of 6 hours [20]
with maintained predictive ability of S100B. It seems rea-
sonable that a time window of 6 hours may be more
applicable to this population and should be considered in
future studies and/or clinical practice. Finally, deviation
from the guidelines was seen. Although this was allowed in
the study protocol, reasons for the deviation were not
explored in depth and would have been an interesting
point to examine. Future studies should include a
comparison of clinical rules with unstructured physician
assessment, in order to fully explore this aspect, including
reasons for deviation from a guideline.
Conclusion
Incorporation of S100B into existing guidelines for man-
agement of MHI in adults is safe and effective. Adult
MHI patients without additional risk factors and with
normal S100B levels within 3 hours of injury can safely
be discharged from the hospital.
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